A Phase II Randomized, Placebo Controlled, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients Upon Discharge or Following Hospitalization for Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction

Trial Profile

A Phase II Randomized, Placebo Controlled, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients Upon Discharge or Following Hospitalization for Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs QGC 001 (Primary)
  • Indications Chronic heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms QUID-HF
  • Sponsors Quantum Genomics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 15 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 15 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top